A cytoplasmic motif in HLA-E that drives clathrin-mediated endocytosis and VCP-associated postendocytic trafficking
Abstract
Human Leukocyte Antigen E (HLA-E) is a nonclassical MHC class I molecule that exhibits dual immunological functions in regulating natural killer (NK) cells and T cells through unusual trafficking patterns. We previously reported that HLA-E surface expression is low and transient due to its cytoplasmic tail and dominant VL9 peptide, making it a dynamic indicator of cellular status for NK cell surveillance. Here, we identify a sequence motif in the HLA-E cytoplasmic tail that enables rapid internalization via clathrin-mediated endocytosis (CME) through interaction with the adaptor protein 2 (AP-2) complex. Following internalization, HLA-E is routed to endosomes, where the same cytoplasmic motif and peptide loading together facilitate its reappearance on the cell surface—a process influenced by valosin-containing protein (VCP). Our findings reveal previously unrecognized endosomal trafficking pathways and regulatory mechanisms that distinguish HLA-E from classical HLA class I molecules, with broad implications for understanding the immunoregulatory roles of HLA-E.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (11)
Wanlin He
Center for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford
Andreas Damianou
Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford
Iolanda Vendrell
Klaus Früh
Daowen I. Yin
Department of Structural and Molecular Biology, Division of Biosciences, University College London
Frances M. Brodsky
Department of Structural and Molecular Biology, Division of Biosciences, University College London
Benedikt M. Kessler
Simon Brackenridge
Center for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford
Persephone Borrow
Center for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford
Geraldine M. Gillespie
Center for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford
Andrew J. McMichael
Center for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford